menu search

KYKOF / Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating

Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating
Kyowa Kirin shares are viewed as a cheap option on the positive outcome for the atopic dermatitis drug being developed with Amgen. The company's recent track record for new drug trial success has been poor, but the partnership with Amgen provides reassurance. Kyowa Kirin is well-capitalized with a strong balance sheet and free cash flow, making the shares attractive on current consensus forecasts. Read More
Posted: Sep 24 2023, 23:33
Author Name: Seeking Alpha
Views: 102621

KYKOF News  

Kyowa Kirin to acquire Orchard Therapeutics for $478 mln

By Reuters
October 5, 2023

Kyowa Kirin to acquire Orchard Therapeutics for $478 mln

Japanese pharmaceutical firm Kyowa Kirin said on Thursday it would acquire Britain-based biopharmaceutical company Orchard Therapeutics for $477.6 mil more_horizontal

Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating

By Seeking Alpha
September 24, 2023

Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating

Kyowa Kirin shares are viewed as a cheap option on the positive outcome for the atopic dermatitis drug being developed with Amgen. The company's recen more_horizontal


Search within

Pages Search Results: